Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02717624 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT02717624 · ClinicalTrials.gov record · last posted 2026-07-14

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

StatusActive, Not Recruiting
PhasePhase 1
Started2016-04-20
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma

Amendment record 28 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 28 times since 2016-03-23; most recent amendment 2026-07-13. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2022-01-19
Status change Recruiting→Active, Not Recruitingv12
2018-12-18
Status change Active, Not Recruiting→Recruitingv9
2017-04-13
Status change Recruiting→Active, Not Recruitingv4
Trial Details
NCT Number NCT02717624
Lead Sponsor Acerta Pharma BV
Collaborators: AstraZeneca
Conditions Mantle Cell Lymphoma (MCL)
Enrollment 72 participants
Start Date 2016-04-20
Primary Completion 2022-06-15 (estimated)
Study Completion 2027-08-20 (estimated)
Updated on ClinicalTrials.gov 2026-07-14